The detection of the microsatellite instability (MSI) phenotype and/or mismatch repair deficiency in some colorectal cancers (CRCs)
1–3 has made the identification of Lynch syndrome easier
4–6. A major breakthrough in medical oncology was the discovery of immune checkpoint inhibitors (ICIs), such as anti-PD1 or anti-PDL1 monoclonal antibodies, alone or in combination with anti-CTLA4 monoclonal antibodies
7.